Therefore, our findings may offer new insights into the pharmacological mechanisms that underlie the actions of DADS in inhibiting the growth of CRC and aid in design of new therapies for CRC by targeting the PI3K/AKT/TRIM21/POU2F1 axis. The gene discussed is POU2F1; the disease is colorectal carcinoma.